NASDAQ:ACRV
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. reported net income of −$77.9M in fiscal 2025. Free cash flow was −$65.3M, and the diluted share count rose 14.0%.Summary generated from Acrivon Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−53.9%
Debt / equityn/a
Free cash flow−$65.3M
FCF marginn/a
Share count change+14.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −16 | −33 | −67 | −89 | −84 |
| Net income | −16 | −31 | −60 | −81 | −78 |
| Free cash flow | −14 | −32 | −44 | −68 | −65 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Sep 2, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KDirector or officer change
Jun 17, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 13, 2026 - DEF 14AProxy statement
Apr 30, 2026